IMPACT Therapeutics, Inc. Class H 7630
HKEX · Hong Kong SAR China · Health Technology
HKD 14.16+0.09 (+0.64%)
Market open· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
NANJING, China & BASILDON, England, September 18, 2026--For business and medical media only
IMPACT Therapeutics is set to receive an upfront payment, near-term regulatory milestones, and commercial milestone payments for sales.
IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with Pharmanovia, a global specialty pharmaceutical company which partners with innovative biotech and large pharma to bring innovative specialty medicines to patients, to grant Pharmanovia the exclusive rights to manufacture, develop and commercialise senaparib in Europe, Middle East and North Africa, Australia and New Zealand for maintenance monothera
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.